<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001859061</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001840439</issuerCik>
      <issuerName>BioMea Fusion Inc.</issuerName>
      <secFileNumber>001-40335</secFileNumber>
      <issuerAddress>
        <com:street1>826 Main Street</com:street1>
        <com:city>Redwood City</com:city>
        <com:stateOrCountry>CA</com:stateOrCountry>
        <com:zipCode>94063</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>650-980-9099</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>A2A Pharmaceuticals, Inc.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Stakeholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>UBS Financial Services Inc</name>
        <address>
          <com:street1>1000 Harbor Blvd</com:street1>
          <com:street2>3rd Floor</com:street2>
          <com:city>Weehawken</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07086</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>400000</noOfUnitsSold>
      <aggregateMarketValue>12000000</aggregateMarketValue>
      <noOfUnitsOutstanding>35308622</noOfUnitsOutstanding>
      <approxSaleDate>04/27/2023</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <acquiredDate>04/12/2021</acquiredDate>
      <natureOfAcquisitionTransaction>Pre-IPO   Owner</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>BioMea Fusion Inc.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>4363342</amountOfSecuritiesAcquired>
      <paymentDate>04/12/2021</paymentDate>
      <natureOfPayment>N/A</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>A2A Pharmaceuticals, Inc.</name>
        <address>
          <com:street1>8 Park Pl</com:street1>
          <com:city>Great Neck</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>11024</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>COMMON</securitiesClassTitle>
      <saleDate>03/31/2023</saleDate>
      <amountOfSecuritiesSold>200000</amountOfSecuritiesSold>
      <grossProceeds>6233088</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>A2A Pharmaceuticals, Inc</name>
        <address>
          <com:street1>8 Park Pl</com:street1>
          <com:city>Great Neck</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>11024</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <saleDate>04/20/2023</saleDate>
      <amountOfSecuritiesSold>200000</amountOfSecuritiesSold>
      <grossProceeds>5618000</grossProceeds>
    </securitiesSoldInPast3Months>
    <noticeSignature>
      <noticeDate>04/27/2023</noticeDate>
      <signature>/s/ UBS Financial Services Inc, as attorney-in-fact for A2A Pharmaceuticals, Inc.</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
